Russell Investments Group Ltd. Has $132,000 Position in Surgery Partners, Inc. (NASDAQ:SGRY)

Russell Investments Group Ltd. cut its stake in Surgery Partners, Inc. (NASDAQ:SGRY - Free Report) by 65.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,233 shares of the company's stock after selling 11,778 shares during the period. Russell Investments Group Ltd.'s holdings in Surgery Partners were worth $132,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. Principal Financial Group Inc. acquired a new position in shares of Surgery Partners in the third quarter valued at about $1,469,000. AlphaCentric Advisors LLC purchased a new stake in Surgery Partners during the fourth quarter valued at about $374,000. JPMorgan Chase & Co. lifted its stake in shares of Surgery Partners by 3.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 189,436 shares of the company's stock valued at $6,107,000 after acquiring an additional 5,551 shares during the last quarter. Norges Bank purchased a new position in Surgery Partners during the 4th quarter valued at about $15,796,000. Finally, E. Ohman J or Asset Management AB grew its position in shares of Surgery Partners by 40.3% in the 4th quarter. E. Ohman J or Asset Management AB now owns 1,243,111 shares of the company's stock worth $26,317,000 after buying an additional 357,023 shares during the period.

Insider Activity at Surgery Partners

In other news, CFO David T. Doherty sold 6,733 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $24.02, for a total transaction of $161,726.66. Following the sale, the chief financial officer now owns 150,868 shares in the company, valued at approximately $3,623,849.36. This represents a 4.27 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Harrison R. Bane sold 56,315 shares of Surgery Partners stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $25.64, for a total value of $1,443,916.60. Following the completion of the transaction, the insider now directly owns 107,037 shares of the company's stock, valued at $2,744,428.68. This represents a 34.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 106,622 shares of company stock valued at $2,717,860. Insiders own 2.30% of the company's stock.

Surgery Partners Stock Performance

Shares of SGRY stock traded up $0.56 during mid-day trading on Thursday, hitting $22.51. The stock had a trading volume of 132,548 shares, compared to its average volume of 1,097,346. The firm has a market cap of $2.87 billion, a PE ratio of -46.88, a PEG ratio of 19.21 and a beta of 2.40. The company's 50-day simple moving average is $22.85 and its 200-day simple moving average is $23.93. Surgery Partners, Inc. has a fifty-two week low of $19.50 and a fifty-two week high of $33.97. The company has a debt-to-equity ratio of 0.99, a current ratio of 1.80 and a quick ratio of 1.66.

Surgery Partners (NASDAQ:SGRY - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The company reported $0.39 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.01. The business had revenue of $864.40 million for the quarter, compared to analyst estimates of $828.09 million. Surgery Partners had a negative net margin of 2.03% and a positive return on equity of 2.85%. Sell-side analysts anticipate that Surgery Partners, Inc. will post 0.67 earnings per share for the current year.

Wall Street Analyst Weigh In

SGRY has been the subject of several analyst reports. Benchmark reissued a "buy" rating and issued a $35.00 target price on shares of Surgery Partners in a report on Monday, April 21st. Macquarie lowered their price target on Surgery Partners from $34.00 to $33.00 and set an "outperform" rating for the company in a report on Tuesday, March 11th. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $35.00 target price on shares of Surgery Partners in a research note on Tuesday, March 25th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $34.75.

Surgery Partners Company Profile

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.